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NO's major physiological receptor is the soluble guanylyl
cyclase (sGC). sGC exist as heterodimers of 2 subunits, α/
β. Heterodimerization between both the α and β subunit
is essential for sGC's enzymatic activity. Five subunits,
termed α1, α2, α2i, β1 and β2, have been identified so far;
however, there are only two functional enzyme forms, α1/β1 and α2/β1, that appear to form in vivo at the protein
level. The β2 sGC subunit is the most obscure isoform of
all the subunits and its physiological relevance is until
now unresolved. Here we clearly show a ubiquitous
expression of sGCβ2 in wildtype mice. Cloning of this sub-
unit revealed a 45 base pairs shorter splice variant in the
7th exon along with the predicted sGCβ2 mRNA. This
shorter variant is expressed along with the sGCβ2 in all
major organs. To further characterize the role of this sub-
unit, we have generated a sGCβ2 knockout mice and back-
crossed by speed-congenics. The heme NO binding
domain (HNOB), comprising exons 5, 6 and 7 were
deleted. Analysis of the knockout mice revealed no tran-
scripts of sGCβ2 in all the major organs suggesting the
sGCβ2 knockout mice are complete knockouts. These ani-
mals have been backcrossed by marker assisted backcross-
ing (speed congenics), with over 98 percent of the C57/
BL6J (recipient) background incorporated. The pheno-
typic analysis of these knockout mice will help unravel the
role of this subunit in the NO/cGMP cascade.
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